Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant.

Infections with a range of common community viruses remain a major cause of mortality and morbidity after allogeneic hematopoietic stem cell transplantation. T cells specific for cytomegalovirus (CMV), Epstein-Barr virus (EBV) and adenoviruses can safely prevent and infections with these three most common culprits, but the manufacture of individual T cell lines for each virus would be prohibitive in terms of time and cost. We have demonstrated that T cells specific for all three viruses can be manufactured in a single culture using monocytes and EBV-transformed B lymphoblastoid cell lines (LCLs), both transduced with an adenovirus vector expressing pp65 of CMV, as antigen-presenting cells. Trivirus-specific T cell lines produced from healthy stem cell donors could prevent and treat infections with all three viruses, not only in the designated recipient, but in unrelated, partially-HLA-matched third party recipients. We now provide the details and logistics of T cell manufacture.

[1]  A. Rickinson,et al.  Epitope-specific Evolution of Human CD8+ T Cell Responses from Primary to Persistent Phases of Epstein-Barr Virus Infection , 2002, The Journal of experimental medicine.

[2]  Juan F. Vera,et al.  Optimization Manufacture of Virus- and Tumor-Specific T Cells , 2011, Stem cells international.

[3]  Chung-Che Chang,et al.  Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals , 2006, Nature Medicine.

[4]  U. Gerdemann,et al.  Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  C. Rooney,et al.  Contact-activated Monocytes: Efficient Antigen Presenting Cells for the Stimulation of Antigen-specific T cells , 2007, Journal of immunotherapy.

[6]  Helen E Heslop,et al.  Accelerated Production of Antigen-specific T Cells for Preclinical and Clinical Applications Using Gas-permeable Rapid Expansion Cultureware (G-Rex) , 2010, Journal of immunotherapy.

[7]  Ann M Leen,et al.  Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation , 2010, Expert opinion on biological therapy.

[8]  J. Melenhorst,et al.  Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. , 2010, Blood.

[9]  P. Moss,et al.  Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines , 2003, The Lancet.

[10]  Malcolm K. Brenner,et al.  Identification of Hexon-Specific CD4 and CD8 T-Cell Epitopes for Vaccine and Immunotherapy , 2007, Journal of Virology.

[11]  E. Bloemena,et al.  Differential Immunogenicity of Epstein-Barr Virus Latent-Cycle Proteins for Human CD4+ T-Helper 1 Responses , 2001, Journal of Virology.

[12]  R. Krance,et al.  Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation , 1995, The Lancet.

[13]  S. Riddell,et al.  Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. , 1995, The New England journal of medicine.

[14]  A. Rickinson,et al.  Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. , 2007, Annual review of immunology.

[15]  P. Hanley,et al.  Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. , 2009, Blood.

[16]  C. Rooney,et al.  Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cells. , 2004, Blood.

[17]  H. Heslop,et al.  Cytotoxic T lymphocytes as immune‐therapy in haematological practice , 2008, British journal of haematology.

[18]  Hans-Georg Rammensee,et al.  Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. , 2002, Blood.

[19]  C. Rooney,et al.  Adenoviral infections in hematopoietic stem cell transplantation. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[20]  H. Heslop,et al.  Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantation , 2007, Bone Marrow Transplantation.